Share Twitter LinkedIn Facebook Email Mark Levis, MD, PhD, weighs in on the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed prior FLT3 TKI therapy.
Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani Acute Lymphoblastic Leukemia 3 Mins Read
Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD Acute Lymphoblastic Leukemia 4 Mins Read
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
